Investing

Regenxbio : RGNX

RGNX

Stock Data

$8.06

$2.67 (24.86%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Regenxbio Inc is a pioneering biotechnology firm focused on developing gene therapies for genetic defects. Leveraging its NAV Technology Platform, the company is advancing a diverse pipeline of treatments targeting serious conditions like wet age-related macular degeneration, diabetic retinopathy, Duchenne muscular dystrophy, and various mucopolysaccharidoses. With a commitment to innovation, Regenxbio also collaborates with industry partners, including a significant agreement with AbbVie for international development. Founded in 2008 and based in Rockville, Maryland, Regenxbio is at the forefront of gene therapy research and development.

All Regenxbio Articles

1 Article

Chris MacDonald | Sep 9, 2024 at 8:29 AM EDT

Goldman Sachs Recommends These 3 Growth Stocks As Strong Buys in September

Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS | GS Price Prediction) has to…